Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females
Sponsor: Universiti Putra Malaysia
Summary
Patients with psychiatric disorders, including depression, anxiety, and schizophrenia, often require antipsychotic medications for symptom management. However, metabolic changes, especially weight gain, are a common and challenging side effect of many antipsychotics. Aripiprazole, an atypical antipsychotic, has shown promise in mitigating this adverse effect when used in combination with other antipsychotic medications.
Official title: Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females Receiving Atypical Antipsychotics: A Randomized Clinical Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2024-09-15
Completion Date
2025-04-10
Last Updated
2024-09-19
Healthy Volunteers
No
Conditions
Interventions
Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females
The intervention group will be added 5 mg of aripiprazole as an adjunct with the usual antipsychotic treatment to the females on antipsychotic treatment